Balance Sheet
Cash Flow Statement
Amortizatization of IntangiblesCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashChange in IntangiblesChange in InventoryChange in ReceivablesDepreciation & Amortization (CF)DivestmentsFree Cash FlowGains from Investment SecuritiesGains from Sales and DivestituresNet Cash FlowNet IncomeNon-cash ItemsOther Working Capital ChangesOther financing activitiesShare-based Compensation
Daily Values
Growth Metrics
Income Statement
Others
Ratios

BridgeBio Pharma (BBIO) Cash from Operations (2019 - 2025)

Historic Cash from Operations for BridgeBio Pharma (BBIO) over the last 7 years, with Q3 2025 value amounting to -$109.6 million.

  • BridgeBio Pharma's Cash from Operations rose 3931.64% to -$109.6 million in Q3 2025 from the same period last year, while for Sep 2025 it was -$584.8 million, marking a year-over-year decrease of 2989.59%. This contributed to the annual value of -$520.7 million for FY2024, which is 132.53% up from last year.
  • BridgeBio Pharma's Cash from Operations amounted to -$109.6 million in Q3 2025, which was up 3931.64% from -$80.7 million recorded in Q2 2025.
  • In the past 5 years, BridgeBio Pharma's Cash from Operations registered a high of $74.7 million during Q2 2024, and its lowest value of -$219.5 million during Q1 2024.
  • Its 5-year average for Cash from Operations is -$124.0 million, with a median of -$133.9 million in 2021.
  • As far as peak fluctuations go, BridgeBio Pharma's Cash from Operations plummeted by 27222.28% in 2023, and later surged by 16590.3% in 2024.
  • BridgeBio Pharma's Cash from Operations (Quarter) stood at -$133.9 million in 2021, then surged by 30.36% to -$93.2 million in 2022, then crashed by 33.86% to -$124.8 million in 2023, then crashed by 56.49% to -$195.3 million in 2024, then surged by 43.9% to -$109.6 million in 2025.
  • Its Cash from Operations was -$109.6 million in Q3 2025, compared to -$80.7 million in Q2 2025 and -$199.2 million in Q1 2025.